// App-Quantinova.ai

256 : Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study

Researchers

Presenter

  • Iain B McInnes

Principal Investigators

  • Bruce Kirkham

  • Peter Nash

  • Proton Rahman

  • Alice B Gottlieb

  • Kevin Ding

  • Luminita Pricop

Medical Centers

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Faculty of Medicine, University of Queensland, Brisbane, AUSTRALIA

  • Faculty of Medicine, Memorial University, St John’s, NL, CANADA

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Immunology and Dermatology Franchise, Novartis Pharma AG, East Hanover, NJ

Locations

  • United Kingdom

  • Australia

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Methotrexate

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01752634

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved